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Abstract
Conjugated linoleic acid (CLA) is a mixture of positional and geometric isomers of octadecadienoic
acid [linoleic acid (LA), 18:2n-6]. Although ruminant milk and meat products represent the largest
natural source of CLA and therefore, their concentration in ruminant lipids are of interest to
human health, chemical or physical modifications of CLA should be needed as a means to enhance
oxidative stability, to improve post-ruminal bioavailability, and to increase the clinical application.
In fact, CLA are rapidly decomposed to form furan fatty acids when its are oxidized in air, and the
effectiveness of dietary supplements of CLA may be related to the extent that their metabolisms
by rumen bacteria are avoided. For these reasons, many scientists have examined the effect of
manufacturing and protection on the stability of CLA in ruminants and food products. In this
review, physico-chemical modifications of CLA for ruminal protection such as calcium salt (Ca),
formaldehyde protection (FP), lipid encapsulation (LE), and amide linkage (AL), and for oxidative
stability such as green tea catechin (GTC), cyclodextrin (CD), arginine (Arg), amylase, and
PEGylation are proposed.
1. Background
Conjugated linoleic acid (CLA) are a collective term for a
group of positional (C8,C10; C9,C11; C10,C12; and
C11,C13) and geometric (cis,cis; cis,trans; trans,cis; and
trans,trans) isomers of octadecadienoic acid (linoleic
acid, LA) with a conjugated double-bond system [1]. Also,
the major and most important formation of CLA are the
endogenous desaturation of vaccenic acid (VA) due to the
action of stearoyl-CoA desaturase (SCD; also so-called
delta-9 desaturase) [1,2]. The CLA are effective in protect-
ing tissues from carcinogenesis [2], reducing the develop-
ment of atherosclerosis [3], stimulating the immune
system [4], and inducing enzyme change in mouse liver
[5,6]. These effects appear to be mediated by two isomers
of CLA, and the two biologically active isomers are the
cis9, trans11 and trans10, cis12 [7,8]. Also, it is well
known that the CLA content in ruminant-derived food are
certainly more affected by the animal diet and production
system than by food-manufacturing factors [9]. Several
factors influence the CLA content of food products, such
as temperature, protein, quality, choice of starter cultures,
and period of aging [10]. Variations of CLA content in
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foods are also affected by the animal's diet, animal age
and breed, and seasonal factors [10-12]. Unfortunately,
physical or chemical modification of CLA should be
needed when its are to be used in food systems as fortifiers
or additives. In fact, a number of methods have been used
to prepare "rumen-protected" feed supplements, and their
efficacy can be described by the extent of protection from
rumen bacteria as well as post-ruminal bioavailability
[13]. Also, CLA are extremely unstable in air and cis, cis-
CLA isomers are most susceptible to oxidative degrada-
tion while the four trans, trans-CLA isomers are most sta-
ble in air [14], indicating that the CLA must be protected
from oxidation. This review is attempted to propose vari-
ous physico-chemical modification methods of CLA for
ruminal protection and oxidative stability, and the poten-
tial of clinical applications of CLA is also explained.
2. Origin and structure of CLA
2. 1. Origin of CLA
Polyunsaturated fatty acids (PUFA) other than CLA, with
a conjugated double bond system and with more than
two double bonds, occurred naturally in nature in various
seed oils but their biological activity had to date not been
extensively investigated when compared with data availa-
ble for CLA [15-18]. The first step in the biohydrogenation
of dietary LA resulted in the formation of the cis9, trans11
isomer, due to isomerization and transposition of the
delta-12 double bond [16]. This was the most abundant
natural isomer present in ruminant tissue fats (over 90%
of total CLA) and had been termed rumenic acid (RA)
[16,19]. Further hydrogenation of RA resulted in the pro-
duction of trans11-18:1 VA which was the major trans-
monounsaturated fatty acid present in the fats of rumi-
nant food products (milk, yoghurt, cheese, butter, and
meats) [19,20]. This contrasts with commercial prepara-
tions of CLA where proportions of the two main isomers
were usually equal, although the chemical method for
synthesis will allow a variety of ratios for the two isomers
in the final mixture [16]. Meat from ruminant animals,
particularly the fat associated with meat, was also an
important source of CLA, contributing in the region of 25
to 30% of the total food intake in Western populations
[16,19]. Isomers of CLA could also be synthesized in the
laboratory from C18:2 or from sources high in C18:2,
such as sunflower, safflower, soybean, or corn oils by a
reaction involving alkaline water isomerization [19-22]
and isomerization in propylene glycol [20,21,23]. The
predominant isomer in milk and other dairy products was
the cis9, trans11 with minor but significant proportions of
trans10, cis12 [16,19,20].
2. 2. Structure of CLA
CLA were a series of positional and geometric isomers of
LA where one or both of the double bonds are either in
the cis or the trans configuration and transposed to differ-
ent positions along the acyl chain with the bonds sepa-
rated by a simple carbon-carbon linkage rather than by
the normal methylene group [16,17]. A number of cis-cis,
cis-trans, trans-cis, and trans-trans isomers with the dou-
ble bonds at various locations along the acyl chain, from
carbon-6 to carbon-15, had been identified by various
chemical reductive, chromatographic, and spectroscopic
techniques [16,18,19]. A total of natural CLA isomers had
been found in milk, dairy products, beef, human milk,
and human adipose tissue using silver ion-high perform-
ance liquid chromatography and gas chromatography-
electron ionization mass spectrometry [23-26].
3. Physiological and biological effects of CLA on 
health and disease
There have been few studies that have examined the
effects of CLA or its isomers in humans. Recently, a wealth
of literature available mainly from cell line and animal
studies indicates that CLA and individual isomers (espe-
cially, C9,T11 and T10,C12) may have numerous health
benefits. One of the first studies in healthy adult women
examined the effects of 3 g/day intake of CLA for 64 days
on fat-free mass, fat mass and percentage fat mass com-
pared to sunflower oil (SFO) placebo, and the results
showed that there were no differences in body composi-
tion or any of the parameters examined [27]. However,
two studies from Norway in healthy exercising humans
(CLA, 1.8 g/day) and in overweight and obese humans
(CLA, 1.7, 3.4, 5.1, and 6.8 g/day) for 12 weeks showed
that CLA can decrease fat mass without significantly
affecting body weight [28,29]. Results of the first study in
athletes were encouraging considering that a much lower
dose of CLA (1.8 g/day) produced significant results com-
pared to the second study where the authors concluded
that a dose of 3.4 g/day of CLA was enough to cause reduc-
tion of body fat. Another study in 2001 evaluated the
effects of intake of 4.2 g CLA/day for 4 weeks on changes
in adipose tissue and cardiovascular risk factors in mid-
dle-aged obese men with signs of metabolic syndrome
[30]. In an interesting study from Netherlands, 13-week
intervention with 1.8 or 3.6 g/day CLA in overweight
humans supplemented prior to this with a very-low-calo-
rie diet (which induced weight loss) increased resting met-
abolic rate and lean mass without affecting body weight
regain [31]. Other studies had previously showed a net
decrease in body fat greater than net decrease in body
weight, suggesting that lean mass may have increased in
the subjects [28,29]. Volunteers in both these studies were
either on intensive training programs or exercised for 90
min, three times per week. These studies seem to suggest
that exercise could enhance the fat-lowering effects of CLA
and also help improve lean mass in humans. However,
there is very limited literature on human studies with indi-
vidual and different ratios of isomers, which makes it dif-
ficult to clearly establish the protective role of theNutrition & Metabolism 2008, 5:16 http://www.nutritionandmetabolism.com/content/5/1/16
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physiological and biologically effect of CLA isomers in
improving human health. In fact, recent studies in ani-
mals and humans suggest that CLA may not have adverse
effects with long-term intervention and may actually be
beneficial in reducing fat mass and atherogenic lipids
[32]. Also, very few clinical studies have focused on the
effects of CLA on bone health and cancer, and there are
also differences in the way CLA was supplemented. In
addition, effect of CLA and its isomers on inflammatory
mediators has not been the subject of extensive research in
humans and need to be pursued urgently. Overall, more
well-controlled studies are needed before CLA or enriched
isomers can be recommended to humans with confidence
to improve health and quality of life. Also, evidence for
efficacy in humans is being steadily strengthened by the
results from clinical trials as well as animal toxicology
tests.
4. Ruminal protection of CLA
Since ruminant milk and meat products represented the
largest natural source of CLA and therefore, their concen-
tration in ruminant lipids was of interest to human health
although only trans10, cis12 was primarily mentioned
which was used in the studies to obtain milk fat depres-
sion [33]. A technology to reduce milk fat output in a con-
trolled manner had a potential application as a
management tool [34]. However, the effectiveness of die-
tary supplements of CLA may be related to the extent that
their metabolism by rumen bacteria was avoided [13,34].
Hence, a number of processes had been used to manufac-
ture "rumen-protected" feed supplements, and their effi-
cacies were described by the extent of protection from
rumen bacteria as well as post-ruminal bioavailability
[13,35]. Several methods had been used to reduce the
extent to which lipid supplements were metabolized by
rumen bacteria. These included the formation of calcium
salts [15,36-38], amide linkages [13,36,37], [39-41], for-
maldehyde treatment [15], and lipid encapsulation
[13,30,42,43]. The form of fatty acid required for the pro-
duction of these supplements varies, and became an
important consideration due to the variation in manufac-
turing processes and costs associated with the production
of different lipid forms.
4. 1. Calcium salt
Calcium salts (Ca) of fatty acids had been commercially
used as a dietary lipid supplement for dairy cows, and they
had been experimentally used to provide rumen-pro-
tected supplements of CLA [15,36]. Giesy et al. reported
that milk fat percentage was reduced in a dose-dependent
manner by feeding Ca-CLA [36]. The predicted equation
followed data well and showed the expected decrease in
milk fat percentage as dose increased, indicating that Ca-
CLA provided with the opportunity to regulate milk fat
synthesis with only a minor dietary addition (Fig. 1A).
(A) Relationship between dose of conjugated linoleic acid  (CLA) as calcium salts and milk fat percentage in Holstein  cows on the fifth days of CLA feeding Figure 1
(A) Relationship between dose of conjugated linoleic acid 
(CLA) as calcium salts and milk fat percentage in Holstein 
cows on the fifth days of CLA feeding. Graph illustrates pre-
dicted exponential regression model (y = 1.114 * e-0.033x + 
2.249) (J Dairy Sci 2002, 85:2023–2029). (B) Temporal pat-
tern of milk fat content in cow (n = 3) during intraruminal 
infusion of different rumen-protected conjugated linoleic acid 
(CLA) formulations. Treatments were control (no added 
lipid; •), calcium salt of CLA (▪), and formaldehyde-protected 
CLA () (J Dairy Sci 2005, 88:1685–1693). (C) Temporal pat-
tern of milk fat yield during supplementation of rumen-pro-
tected CLA supplements [amide-protected CLA (AP-CLA): 
lipid-encapsulated-CLA (LE-CLA)] (J Dairy Sci 2004, 87:3010–
3016)
A
B
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These effects were caused by the trans10, cis12 CLA. The
extent of the effect was certainly higher by using the form
of a Ca because it protected the fatty acid from microbial
degradation. Moreover, supplementing dairy cows with
rumen-protected forms of CLA such as Ca-CLA substan-
tially reduced the yield and content of milk fat without
altering other production responses [15]. Similar effects
on milk fatty acid pattern had been reported in previous
studies where cows had received Ca-CLA [37], and studies
involving abomasal infusion of trans10, cis12 CLA, where
effects on de novo synthesized fatty acids became more
pronounced as the dose of trans10, cis12 CLA increased
[38].
4. 2. Formaldehyde protection
Formaldehyde protection (FP) enabled the use of either
FFA or esterified fatty acids [15]. Figure 1B and Table 1
showed that the CLA supplements resulted in a progres-
sive reduction in milk fat content through the first few
days of the treatment period and the proportion of pre-
formed fatty acids in milk fat was increased with CLA
treatment, whereas short- and medium-chain fatty acids
tended to decrease, indicating that both protection forms
such as Ca and FP were effective methods for the formula-
tion of CLA supplements to induce milk fat depression
(MFD) in lactating dairy cows and the transfer of trans10,
cis12 CLA into milk fat for both Ca-CLA and FP-CLA sup-
plements was much lower than that previously reported
when CLA were supplied post-ruminally. As expected, the
CLA treatments resulted in increased concentrations of
trans10, cis12 CLA in milk fat, with the increase for FP-
CLA treatment being greater than the Ca-CLA treatment.
4. 3. Lipid encapsulation
Recent work showed that the FFA and methyl ester forms
of trans10, cis12 CLA were equally effective in reducing
milk fat synthesis when supplied by abomasal infusion
[39]. Also, Perfield et al. observed a gradual reduction in
milk fat yield over the first few days of treatment and a
return to control values when the supplement was termi-
nated [13], and this was similar to changes observed when
trans10, cis12 CLA were abomasally infused [42] or pro-
vided intravenously [43]. It was found that the lipid
encapsulation (LE) of CLA supplement was manufactured
by binding methyl esters of CLA to a silica matrix, and
then coating this complex with hydrogenated soybean oil,
which contained fatty acids in the triglyceride form.
4. 4. Amide linkage
Although Ca and FP of fatty acids had been commercially
used as a dietary lipid supplement for dairy cows, and they
had also been experimentally used to provide rumen-pro-
tected supplements of CLA [36,37], only few studies had
been performed to suggest the rumen-protected supple-
ments of CLA on amide protection (AP) methods. A sim-
ple AP supplement required that the starting material be
FFA, whereas other amide-protected supplements had
been manufactured from oils, and esters or other forms
could be used for FP or LE [40]. Perfield et al. examined
the use of AP and LE as methods to supply CLA [13]. It
was found that the AP supplement provided CLA as FFAs,
whereas the LE supplement provided CLA as methyl
esters, suggesting that the AP-CLAs supplements resulted
in decreased secretion of milk fatty acids of all chain
lengths, but the reduction was relatively greater for milk
fatty acids containing ≤ 16 carbons (Fig. 1C and Table 2).
These results indicated that the AP-CLA supplements were
able to reduce milk fat in a controlled manner with no
adverse effects. Recent work had also reported that the FFA
and methyl ester (ME) forms of trans10, cis12 CLA were
equally effective in reducing milk fat synthesis when sup-
plied by abomasal infusion [39] and CLA-ME could be
Table 1: Intake and milk production results during intraruminal administration of rumen-protected conjugated linoleic acid (CLA) (J 
Dairy Sci 2005, 88:1685–1693).
Treatment1 P
Control Ca-CLA FP-CLA SEM CLA2 Type3
DMI, kg/d 23.6 23.1 23.3 1.13 0.68 0.84
Milk yield, kg/d 21.9 20.6 19.5 2.32 0.31 0.57
Milk fat
% 3.61 2.61 2.34 0.27 < 0.01 0.18
g/d 788 517 441 42 0.02 0.30
Milk protein
% 3.16 3.38 3.48 0.17 0.08 0.40
g/d 690 673 669 50 0.64 0.93
SCC, ×1000 150 114 137 98 0.44 0.52
1Values represent mean from d 6 and 7 for control (no added lipid) and intraruminal administration calcium salts of CLA (Ca-CLA) and 
formaldehyde-protected CLA (FP-CLA).
2Contrast between control and the combined CLA treatments.
3Contrast between Ca-CLA and FP-CLA treatments.Nutrition & Metabolism 2008, 5:16 http://www.nutritionandmetabolism.com/content/5/1/16
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protected from ruminal metabolism and inclusion of RP-
ME-CLA supplement in the diet reduced milk fat content
by 35–40% and significantly increased the concentration
of CLA isomers in milk [41]. Overall, supplementation of
an AP-CLA or a LE-CLA product resulted in similar reduc-
tions in milk fat with no effect on feed intake or milk
yield. Although reduction in milk fat yield had achieved
nadir by the sixth day of supplementation, transfer of
trans10, cis12 CLA into milk fat was similar for both
rumen-protected CLA products, and the AP-CLA and LE-
CLA supplements were able to reduce milk fat in a con-
trolled manner with no adverse effects [13], as this was a
short-term study with very limited animal numbers, fur-
ther research with these supplements would be needed to
verify and extend results.
5. Oxidative stability of CLA
Some of the studies had shown that CLA acted as an anti-
oxidant although some other studies had been reported
that CLA might be pro-oxidant. Anti-oxidant activity of
CLA was observed in mammary gland tissues from rats fed
with CLA, when evaluated by the thiobarbituric acid reac-
tive substances (TBARS) values [44]. However, CLA did
not reduce TBARS values in pork patties mixed with CLA
[44,45] and in in vitro study; CLA were oxidized as rapidly
as LA [12,46]. In fact, CLA were extremely unstable in air
and cis, cis-CLA isomers were most susceptible to oxida-
tive degradation while the four trans, trans-CLA isomers
were most stable in air under same conditions [14]. More-
over, CLA were oxidized faster than LA, suggesting that a
conjugated double bond was more vulnerable to auto-oxi-
dation than a non-conjugated double bond. This was in
agreement with those of previous observations
[14,47,48], indicating that CLA must be protected from
oxidation when it was to be used in food systems as forti-
fiers or additives.
5. 1. Green tea catechins
Dietary supplements containing green tea extracts were
expected to be comprised of polyphenolic compounds
called catechins, which were commonly obtained from
green tea. The catechins were believed to act as anti-oxi-
dants and free radical scavengers having chemo-preventa-
tive behavior as well as protection against coronary heart
disease and attenuation of high blood pressure [40]. The
catechins common to all green teas were (-)-epigallocate-
chin (EGC), (+)-catechin (C), (-)-epigallocatechin-3-gal-
late (EGCG), (-)-epicatechin (EC), and (-)-epicatechin
gallate (ECG) [49]. Also, it was known that green tea cate-
chins were strong anti-oxidants [50]. Seo et al. reported
that CLA was more stable than LA in the aqueous system
when 2,2'-azobis(2-amidinopropan) dihydrochloride
was used as a free radical initiator [51]. Also, jasmine
green tea catechins (GTC) (200 ppm) were effective as an
anti-oxidant in protecting CLA from oxidation and the
inhibition of 200 ppm GTC on CLA oxidation was even
stronger than that of 200 ppm butylated hydroxytoluene
(BHT) under the same conditions [40]. The oxygen con-
sumption test showed that the oxygen uptake by the CLA
samples was considerably more unstable than LA,
whereas addition of 200 ppm GTC significantly decreased
the oxygen uptake by CLA as compared with the control
CLA samples (Fig. 2A). It is noteworthy that 200 ppm
GTC is more effective than 200 ppm BHT in protecting
CLA from oxidation. It is known that canola oil contains
α-tocopherol and it is also possible that GTC and α-toco-
pherol have a synergistic effect on the oxidation of CLA
when added in canola oil [52]. Also, feeding canola seed
to lactating dairy cows resulted in milk fat with higher
proportions of healthful fatty acids without affecting milk
yield or composition of milk [53].
5. 2. Cyclodextrin/CLA complex
α-, β-, and γ-cyclodextrins, consisting of 6, 7, and 8 D(+)-
glucopyranose units connected by α(1→4) glucosidic
bond, respectively, are well known cyclodextrins (CDs)
for food industry [54]. The CDs were known to form
inclusion complexes with various compounds, ranging
from polar to highly non-polar agents [55]. Also, PUFA
encapsulated in α- and β-CDs had been shown to protect
completely against oxidation even in pure oxygen [56].
Oxidative stability of CLA encapsulated in α-, β-, and γ-
cyclodextrins (designated as CLA/CDs microencapsules)
was studied by measuring the headspace-oxygen deple-
tion in airtight serum bottles and by measuring the perox-
ide values (POV) [57]. It was found that CLA/α-CD
microencapsules at a 1:4 mole ratio completely protected
CLA from oxidation, when oxidized at 35°C and a 1:6
mole ratio of CLA/β-CD was required to give a protective
Table 2: Performance of lactating dairy cows receiving rumen-
protected supplements of conjugated linoleic acid (CLA)1,2 (J 
Dairy Sci 2004, 87:3010–3016).
Treatment
Variable Control AP-CLA LE-CLA SEM P3
DMI, kg/d 30.6 31.6 30.4 0.9 0.50
Milk, kg/d 40.5 42.6 42.7 3.5 0.32
Milk fat
% 3.23a 2.37b 2.34b 0.15 < 0.001
kg/d 1.272 1.004b 0.992b 0.079 < 0.001
Milk protein
% 2.55 2.51 2.58 0.12 0.07
kg/d 1.001b 1.063a 1.086 0.023 0.02
a,bMeans within a row with different superscripts differ.
1Supplements were amide-protected CLA (AP-CLA) and lipid-
encapsulated CLA (LE-CLA).
2Values represent an average of day 6 and 7 of supplementation.
3Statistical probability of treatment effects.Nutrition & Metabolism 2008, 5:16 http://www.nutritionandmetabolism.com/content/5/1/16
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effect similar to that exhibited by CLA/γ-CD microencap-
sules at a 1:4 mole ratio (Fig. 2B). The protective efficiency
of CDs for CLA oxidation may be, in part, attributed to the
hydrophobicity of the inner cavity of CDs, which facili-
tated insertion of the conjugated diene portion into the
CD cavity, and the cavity of the CDs, which was possibly
large enough to incorporate some oxygen molecules and
create a miniature reaction chamber to facilitate the reac-
tion between CLA and oxygen, suggesting that physical
interference by CDs was not a negligible factor for the oxi-
dative stability of CLA. Further study will be required to
explore the structural features of CLA/CDs microencap-
sules. It was of significance to note that β-CD was an
appropriate material with which to microencapsulate CLA
for industrial use, because of its adequate protective
effects for CLA oxidation and because it was much lower
in cost than other CDs.
5. 3. Arginine/CLA complex
Arginine (Arg), a water-soluble amino acid, was known to
be a substrate of nitric oxide synthase and regulate vascu-
lar function and blood pressure homeostasis, and thus
prevent cardiovascular disease [58]. Also, Arg had some
protective roles against oxygen radical attack possibly due
to its direct chemical interaction with oxygen radicals
[59]. Kim et al. reported that hydroperoxide production
from CLA increased about 12-fold at 10 hr after heat treat-
ment at 100°C, whereas Arg/CLA complex did not exhibit
significant hydroperoxide production [60]. The Arg/CLA
complex showed synergistic anti-oxidant activity in a 2,2'-
azinobis(3-ethylbenzothiazoline)-6-sulfonic acid (ABTS)
radical scavenging assay (Fig. 3). It was found that Arg/
CLA complex at 20 mM scavenged 89% of ABTS radicals
in 3 h, whereas CLA alone quenched only 48% under the
same conditions, suggesting that a hydrophilic Arg/CLA
complex exhibited enhanced oxidative stability and anti-
oxidant activity, which may expand the scope of CLA
applications in various food industries. Recent research
had been aimed to elucidate the physiological back-
ground of CLA-inducing reduction in adipose tissue mass
[61,62]. However, some concerns had been aroused on
the potential implication of the CLA in insulin resistance
and fatty liver under certain conditions [63-65]. Because
Arg infusion was known to have a preventive role in the
insulin resistance by decreasing the total plasma homo-
cysteine concentration [66] and antioxidant capacity
[66,67], the formation of Arg/CLA complex could allevi-
ate the potential side effects, if any, resulted from the high
dose of CLA. Thus, the presence of Arg in the form of com-
plex with CLA may expand the scope of the application of
CLA as a health-promoting agent.
5. 4. Amylase/CLA complex
Most of the interest in amylase/lipid complexes focused
on their technological importance in the starch food sys-
tem, since they modified the texture and structural stabil-
ity of starch based-product (e. g., reduction in stickiness,
improved freeze-thaw stability, and retardation of retro-
(A) Headspace-oxygen consumption profile of LA and CLA  with or without addition of 200 ppm GTC or 200 ppm BHT  at 90°C Figure 2
(A) Headspace-oxygen consumption profile of LA and CLA 
with or without addition of 200 ppm GTC or 200 ppm BHT 
at 90°C. Data are expressed means ± SD for n = 5 samples. 
Means at the same time point with different superscript let-
ters (a-d) differ significantly (p < 0.05) (J Agric Food Chem 
2000, 48:3072–3076). (B) Headspace-oxygen depletion by 
CLA/α-CD microencapsulations. The CLA/α-CD microen-
capsules were incubated in a shaking incubator (35°C, 250 
rpm) for a period 80 h. Two and three asterisks represent 
that headspace-oxygen depletion is significantly different 
from that of the control, incubated for 80 h, at p < 0.01 and p 
< 0.001 levels, respectively, by Tukey's w significant test (J 
Agri Food Chem 2000, 48:3922–3929).
A
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gradation) [68,69]. Other researchers studied amylase/
lipid complexes in view of their contribution to the bioa-
vailability of starch, in terms of its enzymatic digestion
[70]. It was shown that the V-form could be produced
from mono- and di-glycerides, and saturated fatty acids, as
well as un-saturated fatty acids [70,71]. The protection
against oxidation afforded to CLA by its inclusion in an
amylase complex demonstrated the potential of the com-
plexes, especially those created in water/dimethyl sulfox-
ide (DMSO) solution, to efficiently protect CLA from
oxidation [72]. It was shown that the peaks of the diffrac-
tograms obtained from complexes made in KOH/HCl
solution were narrower than those obtained from com-
plexes created by water/DMSO solution, indicating that
these complexes were composed of large crystals. Also, the
complexes created in water/DMSO solution at 90°C
revealed globural structures of heterogeneous nature with
an average z-range of 71.6 ± 59 nm and diameter of 152 ±
39 nm. Fig. 4 shows oxidation of CLA on each water/
DMSO and KOH/HCl solution, indicating that the protec-
tive effect of complexes against CLA oxidation was higher
for complexes created in water/DMSO solution than that
for KOH/HCl solution, suggesting that complexes created
in water/DMSO solution exhibited better protective abil-
ity from oxidation. Hence, these results indicate that the
amylase/lipid complex system could serve as a vehicle for
delivery of PUFA to the intestine and potential use of amy-
lase/lipid complexes could be supplementation of various
stable foods with PUFA.
5. 5. PEGylation
Poly(ethylene glycol) (PEG) was a nontoxic, water-solu-
ble polymer widely used for stabilizing colloids in foods
and paints and in formulating pharmaceuticals and cos-
metics [73]. Generally, covalent attachment of activated
PEG to proteins altered protein properties, such as
increased solubility and stability in organic solvents,
increased thermal stability, and reduced immunogenicity
and antigenicity, in ways that extend their potential uses
[74-76]. Also, PEGylation provided a higher stability
owing to the formation of core-shell type nanoparticels
(NPs) when compared to the non-modified drug [77]. In
fact, PEGylated drugs such as core-shell type polymeric
NPs increased stability in air, light, pH, and temperature
[74,76]. Support for these results, as shown in Fig. 5A, the
concentration of intact all-trans retinoic acid (atRA) in the
methanol solution rapidly decreased during incubation at
room temperature under light exposure whereas the rate
of PEGylated atRA (PRA) degradation was very slow [78].
Also, we previously reported that PEGylated CLA (PCLA)
had increased bioavailability than CLA due to the bio-
compatible and hydrophilic properties of PEG, and perox-
isome proliferator activated receptor gamma 2-induced
adipogenesis was reduced by PCLA [79]. In addition, we
further demonstrated that a time-dependent effect on
lipolysis and p-extracellular signal-related kinases (ERK)
expression was observed for PCLA-treated, but not for
CLA-treated cultures [80], suggesting that the induction
by PCLA of mitogen-activated protein kinase kinase
(MEK)/ERK mitogen-activated protein kinase (MAPK)
activation was linked to secretion of adipo-cytokines,
interleukin-6 (IL-6), and interleukin-8 (IL-8), in time-
dependent manners. Our findings provide support for a
role for PCLA as a pro-drug in the regulation of metabo-
lism in adipose tissue. Moreover, we showed that the level
Kinetics of reaction of ABTS radicals with (a) CLA, (b) Arg,  and (c) Arg-CLA Figure 3
Kinetics of reaction of ABTS radicals with (a) CLA, (b) Arg, 
and (c) Arg-CLA. Each test compound at 0, 1, 2, 5, 10, 15, 
and 20 mM was reacted with 100 μM ABTS radicals. Error 
bars represent standard deviations of each data point (n = 3) 
(J Agric Food Chem 2004, 52:439–444).Nutrition & Metabolism 2008, 5:16 http://www.nutritionandmetabolism.com/content/5/1/16
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of headspace oxygen decreased by PCLA was lower than
that decreased by CLA, indicating that the oxidation of
CLA was significantly protected by PEGylation, as shown
in Fig. 5B (unpublished data). Hence, observations with
PEGylation regarding their biological and CLA-protected
effects are encouraging and their use in a variety of biolog-
ical activity, oxidative stability and post-ruminal bioavail-
ability must not be ignored.
6. Summary
CLA have numerous potential health benefits, and the fats
from milk and meats of ruminants are the richest natural
dietary sources of CLA. Manipulating the diets of dairy
and beef cattle and altering management practices on the
farm could enhance the CLA contents of milk and dairy
products and beef products. Also, the CLA contents of
milk, dairy products, meat, and meat products vary
widely, and the CLA intake by humans have the potential
to increase to a level that have been shown to reduce the
incidence of cancer in animal models through the con-
sumption of CLA-enriched dairy and beef products. How-
ever, CLA are rapidly decomposed to form furan fatty
acids when its are oxidized in air, and the effectiveness of
dietary supplements of CLA may be related to the extent
that their metabolism by rumen bacteria is avoided. To
overcome with these phenomena, many investigations
have examined the effect of manufacturing and protection
on stability of CLA in ruminants and food products such
as rumen-protected methods including Ca, Fa, AP, and LE,
and oxidative stability methods such as GTC, CD, Arg, and
amylase. All of these modifications, however, there are
short-term study with very limited animal numbers; fur-
ther research with these supplements will be needed to
verify and extend results. Also, before CLA supplementa-
tion are recommended for human beings, controlled
research studies using single isomers of CLA need to be
completed to determine its efficacy and safety. Moreover,
it is still questionable whether high levels of trans10, cis12
in milk are indeed desired-especially taking into consider-
ation that trans10, cis12 is not really a naturally occurring
fatty acid although CLA, specifically trans10, cis12, might
be detrimental to human health. However, suffice it to say
that observations with CLA regarding their possible health
effects are encouraging and their use in a variety of func-
tional foods are a distinct possibility that should be inter-
ested.
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Headspace-oxygen analysis of complexes created at 90°C 
(A), 60°C (B), and 30°C (C) in water/DMSO solution (•) and 
by KOH/HCl solution (▪), with comparison to free CLA(s) 
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Stability test of PRA Figure 5
(A) Stability test of PRA. At specific time intervals, changes in the absorbance were determined through UV absorbance spec-
troscopy at 350 nm. The concentration of intact RA in the methanol solution rapidly decreased as compared to that of PRA 
during incubation at room temperature under light exposure. Each experiment was performed in triplicate. Values are means ± 
SD (J Nutr Biochem 2007, 18:322–331). (B) Headspace-oxygen depletion by CLA and PCLA. Headspace oxygen in the sample 
bottles was analyzed by injecting a 100 μL headspace air sample into a HP 5890 GC (Avondale, PA), equipped with a stainless 
steel molecular sieve column (13×, 80:100; Alltech, Deerfield, IL) and a thermal conductivity detector. High purity helium 
(99.99%) was used as the carrier gas. The flow rate was 40 mL/min. The GC oven temperature was maintained at 40°C. The 
injector port and detector temperatures were maintained at 120 and 150°C, respectively. Each sample was analyzed in tripli-
cate. Oxygen contents were quantified by an HP 3396A integrator (unpublished data).
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